Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Pharma Keep Up With The Challenges Of Digital Healthcare?

Executive Summary

The digital revolution is transforming the world of healthcare, which is awash with new technologies and floods of data. In this thought leadership article written in partnership with CMS, Scrip considers the opportunities and challenges for pharma, in light of progress to date.

You may also be interested in...



Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

Y-mAbs Gives Thanks For First Approved Drug Danyelza

US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.

Biogen Bets Big To Bag Sage Depression And Tremor Drugs

Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.

Topics

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel